Our new patient-centric world has already gone “beyond the pill”, and now it’s going beyond the patient. There’s a growing awareness that we need to look after the friends and family w
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh